Atypical Antipsychotic. Brexpiprazole 0.5, 1, 2, 3, 4 mg.
F.C. TABS.: 28. Adjunctive tmt. of Major Depress. Disor.: The recom. start. dosage for brexipiprazole as adjunctive tmt. is 0.5 mg or 1 mg×1/d, orally with/without food.
Titrate to 1 mg once dly,. then up to the target dosage of 2 mg once dly. Dosage incr. should occur at wkly. intervals based on the pt’s. clinical response and tolerability. The max. recomm. dly. dosage is 3 mg. Periodically reassess to determine the continued need and appropriate dosage for tmt.
Tmt. of Schizophrenia: The recom. start. dosage for Brexipiprazole is 1 mg×1/d. on Days 1-4, taken orally with/without food.
The recom. target brexipiprazole dosage is 2 mg-4 mg×1/d. Titrate to 2 mg×1/d once dly. on Day 5 through Day 7, then to 4 mg on Day 8 based on the pts. clinical response and tolerability. The max. recom. dly. dosage is 4 mg.
Dosage Adjustm. for Hepatic Impair.: For pts. with moderate to severe hepatic impair. (Child-Pugh score ≥7), the max. recom. dosage is 2 mg×1/d for pts. with MDD, and 3 mg×1/d for pts. with schizophrenia.
Dosage Adjust. for Renal Impair.: For pts. with moderate, severe or end-stage renal impair. (CLcr<60 mL/minute), the max. recom. dosage is 2 mg×1/d for pts. with MDD and 3 mg×1/d for pts. with schizophrenia.
As adjunct. ther. to antidepressants for the tmt. of major depressive disorder (MDD).
For tmt. of schizophrenia.
C/I: Patients with a known hypersensitivity to brexpiprazole or any of its component.
Reactions have included rash, facial swelling, urticaria, and anaphylaxis.

LMWH. Enoxaparin (as sodium) 2000 IU, 4000 IU, 6000 IU, 8000 IU, 10000IU.
PREFILL.SYR. (sol. for inj.): 2,6,10,20,50 × 2,000 IU (20 mg)/0.2 mL; 2,6,10,20,30,50 × 4,000 IU (40 mg)/0.4 mL; 2,6,10,12,24, 30 × 6,000 IU (60 mg)/0.6 mL, 8,000 IU (80 mg)/0.8mL, 10,000 IU (100 mg)/1 mL.
Dosage must be individ. adjust. by phys. accord. medic. condit. of the pt. See lit.
Prophylaxis of VTE  in moder. & high risk surgical patients, in particular those undergoing orthopaedic or general surgery includ. cancer surg.
Prophylaxis of venous thromboembol. dis. in medical pts. with an acute illness (such as acute heart failure, respirat. insufficiency, severe infec. or rheumatic dis.) and reduced mobility at increased risk of venous thromboemb.
Tmt. of DVT and PE, exclud. PE likely to require thrombolytic ther. or surgery. Prevention of thrombus formation in extra corporeal circulation during haemodialysis.
Acute coronary syndr.:
- Tmt. of unstable angina and Non ST-segment elevation MI (NSTEMI), in comb.  with oral acetylsalicylic acid.
- Tmt. of acute ST-segment elevation myocardial infarction (STEMI) include. pts. to be managed medically or with subsequent percutan. coronary intervent. (PCI).
C/I: Hypersens. enoxaparin sodium, heparin or its derivate., includ. other LMWH.
History of immune mediated heparin-induced thrombocytop. (HIT) within the past 100 days or in the presence of circulat. antibodies.
Active clinically significant bleed., conditions with a high risk of hemorrhage, includ. recent haemorrhagic stroke, GI ulcer, presence of malignant neoplasm at high risk of bleed., recent brain, spinal or ophthalmic surg. , known or suspected oesophageal varices, arteriovenous malformat., vasc. aneurysms or major intraspinal or intracerebral vasc. abnormalities; Spinal or epidural anaesthesia or loco-regional anaesthesia when enoxaparin sodium is used for tmt. in the previous 24 hrs.

Medical Device. Hypromellose 89.9%, Citric Acid 6%, Sodium Citrate 4%, Benzalkonium Chloride 0.1%, Menthol <0.1%.

Monoclonal Antibody. Lanadelumab 300mg/2ml.
VIAL (sol. for  inj.): 1×2ml. Each vial is intended for single use only.
The recom. init. dose is 300 mg lanadelumab every 2 wks. by SC admin. only. In pts. who are stably attack free on tmt., a dose reduct. of 300 mg lanadelumab every 4 wks. may be considered, especially in pts. with low wt.
The drug is not intended for tmt. of acute HAE attacks. If a dose is missed, the patient should be instructed to administer the dose as soon as possible ensuring at least 10 d. betwn. doses. No dose adjust. is required in pts. above 65 yrs. of age, or patients with renal or hepatic impair. The inject. should be restricted to the recom. inj. sites: the abdomen, the thighs, and the upper outer arms. Rotation of the inj. site is recom. This drug may be self-admin. or admin. by a caregiver only after pt. training on SC inj. See lit.
Routine prevent. of recurrent attacks of hereditary angioedema (HAE) in pts. aged 12 yrs. and older.
C/I: Hypersens.

Antibacterial. Chlorhexidine Digluconate 0.2% w/v.
BOTTLE (oral local sol.)1×300 ml. The usual dose is 10 ml ×2/d rinse for 1 min.
Gingivitis: recom. for use for 1 mnth.
Ulcerat. and candida infec.: use an addit. 2 days after the area is healed.
Mouth inflamm. cause by dentures: clean and soak the dentures in mouthwash for 15 min. twice dly.
Antibact. sol. for the disinfect. of the mouth: As an aid to maintain. oral hygiene. As an aid in the tmt.& prevent. of gingivitis.
Inhib. of formation of dental plaque.
For use in aphtous ulcerat. & oral candidal infec. (e.g., denture stomatitis and thrush).
For use in a post-periodontal surgery or tmt. regimen to promote gingival healing.
C/I: Hypersens.

Meningococcal Vaccine. Meningococcus B, multicomponent vaccine (subfamily A1,2,3) 60 mcg, Meningococcus B, multicomponent vaccine (subfamily B1,2,3) 60 mcg.
VIAL (susp. for IM inj.): 1,5,10 × 0.5ml.
Primary series: 2 doses (0.5 ml each) admin. at a 6 mnth. interval.
3 doses: 2 doses (0.5 ml each) adm. at least 1 mnth. apart, followed by a 3^rd dose at least 4 mnths. after the 2^nd dose.
Booster dose: A booster dose should be consid. follow. either dosing regimen for individuals at continued risk of invas. meningococcal dis.
Other ped. population: not indicated for child. under 10 yrs. old.
Active immunisation of individ. 10 yrs. and older to prevent invas. meningococ. dis. caused by Neisseria meningitidis serogroup B.
The use of this vaccine should be in accordance with official recommendations.
C/I: Hypersens.